文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-PSMA PET/CT与177Lu-PSMA SPECT/CT病灶自动分割:双中心研究中PET引导SPECT的附加价值

Automatic lesion segmentation in ⁶⁸Ga-PSMA PET/CT and ¹⁷⁷Lu-PSMA SPECT/CT: added value of PET-guided SPECT in a bicentric study.
PubMed 文献 · EJNMMI Res · 2026-07-01

结果显示PET/CT分割中PET-only与联合模型性能相当,而SPECT/CT分割中PET引导模型在外部验证中显著优于SPECT-only模型,提示PET引导策略可改善SPECT病灶分割。

要点

  • PET/CT分割中PET-only与联合模型性能相当,DSC内外验证分别约0.83与0.76–0.77。
  • SPECT/CT分割中PET引导模型外部验证DSC 0.78,显著优于SPECT-only的0.70。

核心结论

  • PET-only与联合PET+SPECT模型在PET图像上性能相似。
  • 将PET来源的分割作为先验信息倾向于改善SPECT/CT病灶分割,该PET引导策略利用了PET更高的空间分辨率,是迈向全自动提取体积与剂量学生物标志物的关键一步。

研究设计与样本

  • 训练四种nnU-Net模型:M1仅PET/CT、M2仅SPECT/CT、M3联合PET/CT+SPECT/CT(推理时单模态输入)、M4以PET/CT分割作为先验输入的SPECT/CT。
  • 模型先在HBCC数据上训练和内部验证,再在完整HBCC队列上重训练并在NUH数据上外部验证。

主要发现

  • PET/CT分割中M1与M3性能可比:M1的DSC内部0.83 ± 0.19、外部0.76 ± 0.22;M3的DSC内部0.83 ± 0.16、外部0.77 ± 0.21。
  • SPECT/CT分割中PET引导模型M4结果最佳:DSC内部0.63 ± 0.24、外部0.78 ± 0.14;PPV内部0.65 ± 0.26、外部0.75 ± 0.23。
  • 与SPECT-only模型M2(DSC内部0.61 ± 0.26、外部0.70 ± 0.25;PPV内部0.63 ± 0.25、外部0.71 ± 0.24)相比,M4在内部验证中DSC差异无统计学意义(p = 0.35),在外部验证中差异有统计学意义(p = 0.014)。

关键数值与推荐

  • PET/CT分割性能以DSC评价:M1内部0.83 ± 0.19、外部0.76 ± 0.22;M3内部0.83 ± 0.16、外部0.77 ± 0.21。
  • SPECT/CT分割性能以DSC和PPV评价:M4的DSC内部0.63 ± 0.24、外部0.78 ± 0.14,PPV内部0.65 ± 0.26、外部0.75 ± 0.23。
  • M2的DSC内部0.61 ± 0.26、外部0.70 ± 0.25,PPV内部0.63 ± 0.25、外部0.71 ± 0.24。
  • M4与M2的DSC比较:内部验证p = 0.35,外部验证p = 0.014。

临床怎么用

  • 在SPECT/CT分割中可考虑引入PET/CT分割结果作为先验信息,以利用PET更高空间分辨率改善分割表现。
  • 该自动化分割策略有望支持体积与剂量学生物标志物的全自动提取,服务于前列腺癌个体化治疗。

局限性

  • 原文摘要未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Manual segmentation of prostate cancer metastases on PSMA PET/CT and SPECT/CT is time-consuming and poorly scalable, particularly in highly metastatic patients. This study evaluated nnU-Net-based automatic segmentation models trained on PET and SPECT either separately or jointly and assessed whether PET-derived information can improve SPECT lesion segmentation. Seventy-three patients with metastatic castration-resistant prostate cancer treated with ¹⁷⁷Lu-PSMA were retrospectively included: 48 from the Henri Becquerel Cancer Center (HBCC) and 25 from Nantes University Hospital (NUH). For each patient, ⁶⁸Ga-PSMA PET/CT and ¹⁷⁷Lu-PSMA SPECT/CT were acquired before and during the first treatment cycle respectively. All images were manually segmented by four nuclear medicine physicians in consensus. Four nnU-Net models were trained: M1 (PET/CT only), M2 (SPECT/CT only), M3 (joint PET/CT+SPECT/CT, unimodal input at inference), and M4 (SPECT/CT with PET/CT segmentation as a priori input). Models were first trained and internally validated on HBCC data, then retrained on the full HBCC cohort and externally validated on NUH data. RESULTS: For PET/CT segmentation, M1 and M3 achieved comparable performance. M1 reached DSCs of 0.83 ± 0.19 (internal) and 0.76 ± 0.22 (external), while M3 achieved 0.83 ± 0.16 (internal) and 0.77 ± 0.21 (external). For SPECT/CT, the PET-guided model M4 (DSC: 0.63 ± 0.24 internal; 0.78 ± 0.14 external; PPV: 0.65 ± 0.26 internal; 0.75 ± 0.23 external) provided the best results. Compared with the SPECT-only model M2 (DSC: 0.61 ± 0.26 internal; 0.70 ± 0.25 external; PPV: 0.63 ± 0.25 internal; 0.71 ± 0.24 external), M4 showed no statistically significant difference in internal validation (DSC p = 0.35), while being statistically significant in external validation (DSC p = 0.014). CONCLUSION: The nnU-Net framework enables accurate lesion segmentation on both ⁶⁸Ga-PSMA PET/CT and ¹⁷⁷Lu-PSMA SPECT/CT. While PET-only and joint PET+SPECT models perform similarly on PET images, incorporating PET-derived segmentations as prior information tends to improve SPECT/CT lesion segmentation. This PET-guided SPECT segmentation strategy leverages the higher spatial resolution of PET and represents a key step towards fully automated extraction of volumetric and dosimetric biomarkers for personalized prostate cancer treatment.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Perret S, Albe L, Edet-Sanson A, et al. Automatic lesion segmentation in ⁶⁸Ga-PSMA PET/CT and ¹⁷⁷Lu-PSMA SPECT/CT: added value of PET-guided SPECT in a bicentric study. EJNMMI Res. 2026. PMID: 42387196. doi:10.1186/s13550-026-01468-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。